CrushSCI.com
125.7平均天数
111中位天数
2最短天数
296最长天数
1402025发文量

Paper Review Records

全部论文审稿周期

27 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

53 天

Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study

作者
Jinmei Zhou; Mengshuang Gao; Daolei Zhou; Zhiwei Zhang; Huan Zhang; Yu Sun; Huan Zhou展开收起
作者单位
1. School of Pharmacy Bengbu Medical University Bengbu Anhui China; 2. Clinical Trial Center The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui China; 3. College of Laboratory Medicine Bengbu Medical University Bengbu Anhui China; 4. Zhuohe Pharmaceutical Group Co., Ltd. Wuxi City Jiangsu Province China展开收起
PDF源文件 DOI 网页
194 天

Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects

作者
Abhijit Chakraborty; Anshu Marathe; Jong Bong Lee; Kari Wiedinger; Britta Zehnpfennig; Carole Schuhler; Simantini Eddy; Michelle Quinlan展开收起
作者单位
1. Novartis Institutes for Biomedical Research East Hanover NJ USA; 2. Insmed NJ USA; 3. Novartis Pharma AG Basel Switzerland; 4. Novartis Pharmaceuticals Corporation East Hanover NJ USA展开收起
PDF源文件 DOI 网页
145 天

A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants

作者
Joseph F. Grippo; Anja Pfaff; Zhongli Xu; Isabell Otto; Claus Thielert; Mihaly Imre; Rui Liu; Wantanee Phuapradit; Yazhong Pei; Cuie Chen; Maria Habel; Renfeng Guo; Camilla Chong展开收起
作者单位
1. InflaRx GmbH Jena Germany; 2. InflaRx Pharmaceuticals, Inc. Ann Arbor MI USA展开收起
PDF源文件 DOI 网页
159 天

A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects

作者
Jianxin Wang; Kai Gu; Mingxuan Zhang; Miao Yu; Pei Zhao; Jing Yu; Xiaohong Guo; Yating Bai; Jie Liu; Xiaoli Wang; Xiaolai Yang展开收起
作者单位
1. School of pharmacy Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region China; 2. Department of Pharmacy Gansu Provincial People's Hospital Lanzhou Gansu Province China; 3. Faculty of Health Sciences (FHS) University of Macau Taipa Macau SAR China展开收起
PDF源文件 DOI 网页
2 天

When Clinical Pharmacology Cannot Wait for Complete Data: Reflections Following the 2026 ACCP Annual Meeting

作者
Amalia M. Issa展开收起
作者单位
1. Editor‐in‐Chief, Clinical Pharmacology in Drug Development USA展开收起
PDF源文件 DOI 网页
55 天

Fed–Fasted Differences in Clindamycin Hydrochloride Capsule Pharmacokinetics: A Pooled Analysis of Publicly Available China CDE Regulatory Summaries

作者
Rui Li; Deshuang Yang; Lang Zhao; Zhengyi Cao; Xiaoyu Li; Mengxi Yang展开收起
作者单位
1. Department of Geriatrics China‐Japan Friendship Hospital Chaoyang District Beijing China; 2. Department of Cardiology of Integrated traditional Chinese and Western Medicine China‐Japan Friendship Hospital Chaoyang District Beijing China; 3. Department of Emergency China‐Japan Friendship Hospital Chaoyang District Beijing China; 4. Department of Hematology China‐Japan Friendship Hospital Chaoyang District Beijing China; 5. Jinan Academician Workstation, Shandong Academy of Chinese Medicine, Lixia District Jinan City Shandong Province China展开收起
PDF源文件 DOI 网页

FAQ

Clinical Pharmacology in Drug Development审稿要多久?

截至2026-11-17,CrushSCI 收录了 Clinical Pharmacology in Drug Development 的 27 篇完整审稿记录。最快一篇从收稿到录用用了 2 天(When Clinical Pharmacology Cannot Wait for Complete Data: Reflections Following the 2026 ACCP Annual Meeting,2026-09-28 收稿,2026-09-30 录用),最慢一篇用了 296 天;平均 125.7 天,中位数 111 天。最快这篇的日期间隔异常短,建议点开原文核对。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。